Semprus BioSciences, a Cambridge, Massachusetts-based venture-backed biomedical company developing a proprietary vascular access product platform Semprus Sustain Performance, has received a $500,000 Phase II-B grant from the National Science Foundation (NSF).

In 2007 and 2008, Semprus BioSciences was awarded Phase I and II grants to develop its novel surface technology and optimize its performance.

The grant is part of the NSF’s Small Business Innovation Research Program and the third such award for Semprus BioSciences.

The grant will support Semprus BioSciences’ product line featuring its long acting Semprus Sustain Performance, which the company claimed is the first non-leaching single surface modification that simultaneously reduces bacterial growth and thrombus formation (blood clots) on medical devices with multi-month efficacy.

Semprus BioSciences CEO David Lucchino said that the NSF’s funding accelerates their timeline to take a giant step forward in bringing a lifesaving and life-enhancing medical device to the market.